ASH Highlights

San Diego—Patients with relapsed or refractory acute leukemia with rearrangement in the KMT2Ar gene, an aggressive and difficult-to-treat leukemia, had an overall response rate of 63% when treated with the investigational agent revumenib, according to data from the single-arm pivotal phase 2 AUGMENT-101 study presented by Ibrahim Aldoss, MD, associate professor, Department of Hematology and Stem Cell Transplant, City of Hope National Medical Center, Duarte, California, at the 65th American Society of Hematology Annual Meeting. Read More ›

Patients undergoing hematopoietic stem-cell transplantation (HSCT) do not derive any benefit from the restrictive diet frequently prescribed to prevent infections, according to the results of a clinical trial presented during the 64th American Society of Hematology Annual Meeting and Exposition. Read More ›

A head-to-head phase 3 clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) has found that zanubrutinib (Brukinsa), a next-generation Bruton tyrosine kinase (BTK) inhibitor, was more effective at preventing disease progression and is better tolerated than ibrutinib (Imbruvica), a first-generation BTK inhibitor that is the current standard of care for this population of patients. Read More ›

The use of low-molecular-weight heparin (LMWH) did not improve the rate of live births among pregnant women with inherited thrombophilia and recurrent miscarriage, according to results of a clinical trial presented during the 64th American Society of Hematology Annual Meeting and Exposition. Read More ›